Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

ABSTRACT:

Importance

Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine.

Objective

To assess the efficacy of fremanezumab compared with placebo for prevention of episodic migraine with a monthly dosing regimen or a single higher dose.

Design and setting

Randomized, double-blind, placebo-controlled, parallel-group trial conducted at 123 sites in 9 countries from March 23, 2016 (first patient randomized), to April 10, 2017, consisting of a screening visit, 28-day pretreatment period, 12-week treatment period, and final evaluation at week 12.

Participants

Study participants were aged 18 to 70 years with episodic migraine (6-14 headache days, with at least 4 migraine days, during 2

SUBMITTER: Dodick DW 

PROVIDER: S-EPMC6583237 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature